Hyderabad based pharma company, Bharat Biotech International Private Limited and the Indian Council Medical Research (ICMR) prepared vaccine, for the Novel Coronavirus or COVID-19 entered the third phase of the vaccine trials.
Krishna Ella, the Chairman and the Managing Director of the Bharat Biotech confirmed the same and said COVAXIN, the potential vaccine for COVID-19 is now undergoing phase 3 trials.
Mr. Ella addressed a virtual programme organised by the Indian School of Business (ISB) on the 16th of November.
Mr. Ella said the Company was also working on another vaccine for COVID-19 which would be in the form of nasal drops and can be ready by next year. He said, “We partnered with ICMR for Covid-19 vaccine as we speak it entered the phase 3 trials.”
According to sources, the Hyderabad based Bharat Biotech is the only pharma company entering BSL3 production facility (Biosafety level 3.)
The phase III trials would be on 26,000 participants and started at the Nizam’s Institute of Medical Sciences (NIMS.)
Stay tuned for further updates.
